Base de dados : MEDLINE
Pesquisa : E02.095.841 [Categoria DeCS]
Referências encontradas : 52 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 6 ir para página                

  1 / 52 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29458535
[Au] Autor:Shahin K; Bouzari M; Wang R
[Ad] Endereço:1​Department of Biology, Faculty of Sciences, University of Isfahan, Hezar Jereeb Street, 81746-73441, Isfahan, Iran.
[Ti] Título:Isolation, characterization and genomic analysis of a novel lytic bacteriophage vB_SsoS-ISF002 infecting Shigella sonnei and Shigella flexneri.
[So] Source:J Med Microbiol;67(3):376-386, 2018 Mar.
[Is] ISSN:1473-5644
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Shigellosis is one of the most important food-borne and water-borne diseases worldwide. Although antibiotics are considered as efficient agents for shigellosis treatment, improper use of these has led to the emergence of antibiotic-resistant Shigella spp. Therefore, finding a new strategy as alternative treatment seems necessary. METHODOLOGY: Different samples from a wastewater treatment plant were used to isolate Shigella spp. specific phages. Physiological properties were determined, and genomic analysis was also carried out. RESULTS: A virulent Siphoviridae bacteriophage, vB_SsoS-ISF002, was isolated from urban wastewater in Iran and showed infectivity to different isolates of both Shigella sonnei and Shigella flexneri. vB_SsoS-ISF002 was stable at different pH values and temperatures. It had a short latent period (15 min), a large burst size (76±9 p.f.u. cell ) and appropriate lytic activity especially at high MOI. Its genome (dsDNA) was 50 564 bp with 45.53 % GC content and 76 predicted open reading frames. According to comparative genomic analysis and phylogenic tree construction, vB_SsoS-ISF002 was considered as a member of the T1virus genus. CONCLUSION: These results indicated that vB_SsoS-ISF002 is a novel virulent T1virus phage and may have potential as an alternative treatment for shigellosis.
[Mh] Termos MeSH primário: Genoma Viral
Shigella flexneri/virologia
Shigella sonnei/virologia
Siphoviridae/genética
Siphoviridae/isolamento & purificação
[Mh] Termos MeSH secundário: Antibacterianos/farmacologia
Composição de Bases
DNA Viral
Disenteria Bacilar/terapia
Genômica
Seres Humanos
Terapia por Fagos
Filogenia
Análise de Sequência de DNA
Shigella flexneri/efeitos dos fármacos
Shigella sonnei/efeitos dos fármacos
Siphoviridae/classificação
Siphoviridae/fisiologia
Águas Residuais/microbiologia
Águas Residuais/virologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (DNA, Viral); 0 (Waste Water)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180221
[St] Status:MEDLINE
[do] DOI:10.1099/jmm.0.000683


  2 / 52 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27776446
[Au] Autor:Bodier-Montagutelli E; Morello E; L'Hostis G; Guillon A; Dalloneau E; Respaud R; Pallaoro N; Blois H; Vecellio L; Gabard J; Heuzé-Vourc'h N
[Ad] Endereço:a Université François Rabelais, UMR 1100 , Tours , France.
[Ti] Título:Inhaled phage therapy: a promising and challenging approach to treat bacterial respiratory infections.
[So] Source:Expert Opin Drug Deliv;14(8):959-972, 2017 Aug.
[Is] ISSN:1744-7593
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Bacterial respiratory tract infections (RTIs) are increasingly difficult to treat due to evolving antibiotic resistance. In this context, bacteriophages (or phages) are part of the foreseen alternatives or combination therapies. Delivering phages through the airways seems more relevant to accumulate these natural antibacterial viruses in proximity to their bacterial host, within the infectious site. Areas covered: This review addresses the potential of phage therapy to treat RTIs and discusses preclinical and clinical results of phages administration in this context. Recent phage formulation and aerosolization attempts are also reviewed, raising technical challenges to achieve efficient pulmonary deposition via inhalation. Expert opinion: Overall, the inhalation of phages as antibacterial treatment seems both clinically relevant and technically feasible. Several crucial points still need to be investigated, such as phage product pharmacokinetics and immunogenicity. Furthermore, given phage-specific features, appropriate regulatory and manufacturing guidelines will need to be defined. Finally, randomized controlled clinical trials should be carried out to establish phage therapy's clinical positioning in the antimicrobial arsenal against RTIs.
[Mh] Termos MeSH primário: Infecções Bacterianas/terapia
Terapia por Fagos
Infecções Respiratórias/terapia
[Mh] Termos MeSH secundário: Administração por Inalação
Animais
Bacteriófagos
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171212
[Lr] Data última revisão:
171212
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161026
[St] Status:MEDLINE
[do] DOI:10.1080/17425247.2017.1252329


  3 / 52 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28664828
[Au] Autor:Colavecchio A; Goodridge LD
[Ad] Endereço:Department of Food Science and Agricultural Chemistry, Food Safety and Quality Program, McGill University, Ste Anne de Bellevue, Quebec, H9X 3V9, Canada.
[Ti] Título:Phage Therapy Approaches to Reducing Pathogen Persistence and Transmission in Animal Production Environments: Opportunities and Challenges.
[So] Source:Microbiol Spectr;5(3), 2017 Jun.
[Is] ISSN:2165-0497
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The era of genomics has allowed for characterization of phages for use as antimicrobials to treat animal infections with a level of precision never before realized. As more research in phage therapy has been conducted, several advantages of phage therapy have been realized, including the ubiquitous nature, specificity, prevalence in the biosphere, and low inherent toxicity of phages, which makes them a safe and sustainable technology for control of animal diseases. These unique qualities of phages have led to several opportunities with respect to emerging trends in infectious disease treatment. However, the opportunities are tempered by several challenges to the successful implementation of phage therapy, such as the fact that an individual phage can only infect one or a few bacterial strains, meaning that large numbers of different phages will likely be needed to treat infections caused by multiple species of bacteria. In addition, phages are only effective if enough of them can reach the site of bacterial colonization, but clearance by the immune system upon introduction to the animal is a reality that must be overcome. Finally, bacterial resistance to the phages may develop, resulting in treatment failure. Even a successful phage infection and lysis of its host has consequences, because large amounts of endotoxin are released upon lysis of Gram-negative bacteria, which can lead to local and systemic complications. Overcoming these challenges will require careful design and development of phage cocktails, including comprehensive characterization of phage host range and assessment of immunological risks associated with phage treatment.
[Mh] Termos MeSH primário: Infecções Bacterianas/terapia
Infecções Bacterianas/veterinária
Doenças dos Bovinos/terapia
Terapia por Fagos/métodos
Doenças das Aves Domésticas/terapia
Doenças dos Suínos/terapia
[Mh] Termos MeSH secundário: Criação de Animais Domésticos/métodos
Animais
Antibacterianos/uso terapêutico
Bactérias/virologia
Infecções Bacterianas/prevenção & controle
Infecções Bacterianas/transmissão
Bacteriófagos/genética
Bovinos
Doenças dos Bovinos/microbiologia
Carne/microbiologia
Aves Domésticas/microbiologia
Doenças das Aves Domésticas/microbiologia
Ruminantes/microbiologia
Suínos
Doenças dos Suínos/microbiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171109
[Lr] Data última revisão:
171109
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170701
[St] Status:MEDLINE
[do] DOI:10.1128/microbiolspec.PFS-0017-2017


  4 / 52 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28661508
[Au] Autor:Reardon S
[Ti] Título:Modified viruses deliver death to antibiotic-resistant bacteria.
[So] Source:Nature;546(7660):586-587, 2017 06 21.
[Is] ISSN:1476-4687
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Antibacterianos/farmacologia
Bactérias/genética
Bacteriófagos/genética
Sistemas CRISPR-Cas/genética
Farmacorresistência Bacteriana/efeitos dos fármacos
Viabilidade Microbiana/genética
Terapia por Fagos/métodos
[Mh] Termos MeSH secundário: Animais
Bactérias/efeitos dos fármacos
Bactérias/imunologia
Bacteriófagos/patogenicidade
Ensaios Clínicos como Assunto
Farmacorresistência Bacteriana/genética
Edição de Genes
Seres Humanos
Camundongos
Viabilidade Microbiana/efeitos dos fármacos
Viabilidade Microbiana/imunologia
Microbiota
[Pt] Tipo de publicação:NEWS
[Nm] Nome de substância:
0 (Anti-Bacterial Agents)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171019
[Lr] Data última revisão:
171019
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170630
[St] Status:MEDLINE
[do] DOI:10.1038/nature.2017.22173


  5 / 52 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28335451
[Au] Autor:Doss J; Culbertson K; Hahn D; Camacho J; Barekzi N
[Ad] Endereço:Old Dominion University, Department of Biological Sciences, 5115 Hampton Blvd, Norfolk, VA 23529, USA. jdoss003@odu.edu.
[Ti] Título:A Review of Phage Therapy against Bacterial Pathogens of Aquatic and Terrestrial Organisms.
[So] Source:Viruses;9(3), 2017 Mar 18.
[Is] ISSN:1999-4915
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:Since the discovery of bacteriophage in the early 1900s, there have been numerous attempts to exploit their innate ability to kill bacteria. The purpose of this report is to review current findings and new developments in phage therapy with an emphasis on bacterial diseases of marine organisms, humans, and plants. The body of evidence includes data from studies investigating bacteriophage in marine and land environments as modern antimicrobial agents against harmful bacteria. The goal of this paper is to present an overview of the topic of phage therapy, the use of phage-derived protein therapy, and the hosts that bacteriophage are currently being used against, with an emphasis on the uses of bacteriophage against marine, human, animal and plant pathogens.
[Mh] Termos MeSH primário: Infecções Bacterianas/terapia
Terapia por Fagos
[Mh] Termos MeSH secundário: Animais
Seres Humanos
Plantas
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170822
[Lr] Data última revisão:
170822
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170325
[St] Status:MEDLINE


  6 / 52 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28286740
[Au] Autor:Drilling AJ; Ooi ML; Miljkovic D; James C; Speck P; Vreugde S; Clark J; Wormald PJ
[Ad] Endereço:Department of Surgery-Otolaryngology Head and Neck Surgery, The University of Adelaide Adelaide, SA, Australia.
[Ti] Título:Long-Term Safety of Topical Bacteriophage Application to the Frontal Sinus Region.
[So] Source:Front Cell Infect Microbiol;7:49, 2017.
[Is] ISSN:2235-2988
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:biofilms contribute negatively to a number of chronic conditions, including chronic rhinosinusitis (CRS). With the inherent tolerance of biofilm-bound bacteria to antibiotics and the global problem of bacterial antibiotic resistance, the need to develop novel therapeutics is paramount. Phage therapy has previously shown promise in treating sinonasal biofilms. This study investigates the long term (20 days) safety of topical sinonasal flushes with bacteriophage suspensions. The bacteriophage cocktail NOV012 against selected for this work contains two highly characterized and different phages, P68 and K710. Host range was assessed against strains isolated from CRS patients using agar spot tests. NOV012 was applied topically to the frontal sinus region of sheep, twice daily for 20 days. General sheep wellbeing, mucosal structural changes and inflammatory load were assessed to determine safety of NOV012 application. NOV012 could lyse 52/61 (85%) of a panel of locally derived CRS clinical isolates. Application of NOV012 to the frontal sinuses of sheep for 20 days was found to be safe, with no observed inflammatory infiltration or tissue damage within the sinus mucosa. NOV012 cocktail appears safe to apply for extended periods to sheep sinuses and it could infect and lyse a wide range of CRS clinical isolates. This indicates that phage therapy has strong potential as a treatment for chronic bacterial rhinosinusitis.
[Mh] Termos MeSH primário: Seio Frontal/microbiologia
Terapia por Fagos/efeitos adversos
Terapia por Fagos/métodos
Sinusite/terapia
[Mh] Termos MeSH secundário: Administração Tópica
Animais
Modelos Animais de Doenças
Especificidade de Hospedeiro
Mucosa Nasal/patologia
Ovinos
Fagos de Staphylococcus/fisiologia
Staphylococcus aureus/virologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170919
[Lr] Data última revisão:
170919
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170314
[St] Status:MEDLINE
[do] DOI:10.3389/fcimb.2017.00049


  7 / 52 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28265031
[Au] Autor:Waters EM; Neill DR; Kaman B; Sahota JS; Clokie MRJ; Winstanley C; Kadioglu A
[Ad] Endereço:Department of Clinical Infection, Microbiology and Immunology, Institute of Infection and Global Health, University of Liverpool, Liverpool, UK.
[Ti] Título:Phage therapy is highly effective against chronic lung infections with .
[So] Source:Thorax;72(7):666-667, 2017 Jul.
[Is] ISSN:1468-3296
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:With an increase in cases of multidrug-resistant , alternative and adjunct treatments are needed, leading to renewed interest in bacteriophage therapy. There have been few clinically relevant studies of phage therapy against chronic lung infections. Using a novel murine model that uses a natural respiratory inhalation route of infection, we show that phage therapy is an effective treatment against chronic lung infections. We also show efficacy against in a biofilm-associated cystic fibrosis lung-like environment. These studies demonstrate the potential for phage therapy in the treatment of established and recalcitrant chronic respiratory tract infections.
[Mh] Termos MeSH primário: Terapia por Fagos
Infecções por Pseudomonas/terapia
Pseudomonas aeruginosa
Infecções Respiratórias/terapia
[Mh] Termos MeSH secundário: Animais
Biofilmes
Doença Crônica
Contagem de Colônia Microbiana
Modelos Animais de Doenças
Camundongos
Camundongos Endogâmicos BALB C
Fatores de Tempo
[Pt] Tipo de publicação:LETTER
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170821
[Lr] Data última revisão:
170821
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170308
[St] Status:MEDLINE
[do] DOI:10.1136/thoraxjnl-2016-209265


  8 / 52 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28258668
[Au] Autor:Al-Wrafy F; Brzozowska E; Górska S; Gamian A
[Ad] Endereço:Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland; Department of Applied Microbiology, Faculty of Sciences, Taiz University, Taiz, Yemen.
[Ti] Título:Pathogenic factors of Pseudomonas aeruginosa - the role of biofilm in pathogenicity and as a target for phage therapy.
[So] Source:Postepy Hig Med Dosw (Online);71(0):78-91, 2017 Feb 14.
[Is] ISSN:1732-2693
[Cp] País de publicação:Poland
[La] Idioma:eng
[Ab] Resumo:Pseudomonas aeruginosa is an opportunistic pathogen that can cause several acute and chronic infections in humans, and it has become an important cause of nosocomial infections and antibiotic resistance. Biofilm represents an important virulence factor for these bacteria, plays a role in P. aeruginosa infections and avoidance of immune defence mechanisms, and has the ability to protect the bacteria from antibiotics. Alginate, Psl and Pel, three exopolysaccharides, are the main components in biofilm matrix, with many biological functions attributed to them, especially with respect to the protection of the bacterial cell from antibiotics and the immune system. Pseudomonas infections, biofilm formation and development of resistance to antibiotics all require better understanding to achieve the best results using alternative treatment with phage therapy. This review describes the P. aeruginosa pathogenicity and virulence factors with a special focus on the biofilm and its role in infection and resistance to antibiotics and summarizes phage therapy as an alternative approach in treatment of P. aeruginosa infections.
[Mh] Termos MeSH primário: Antibacterianos/farmacologia
Terapia por Fagos/métodos
Pseudomonas aeruginosa/efeitos dos fármacos
[Mh] Termos MeSH secundário: Biofilmes/crescimento & desenvolvimento
Infecção Hospitalar/prevenção & controle
Resistência Microbiana a Medicamentos
Seres Humanos
Infecções por Pseudomonas/microbiologia
Pseudomonas aeruginosa/crescimento & desenvolvimento
Fatores de Virulência
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Virulence Factors)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170731
[Lr] Data última revisão:
170731
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170305
[St] Status:MEDLINE


  9 / 52 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28230780
[Au] Autor:Borysowski J; Miedzybrodzki R; Wierzbicki P; Klosowska D; Korczak-Kowalska G; Weber-Dabrowska B; Górski A
[Ad] Endereço:Department of Clinical Immunology, Transplantation Institute, Medical University of Warsaw, Nowogrodzka Str. 59, 02-006 Warsaw, Poland. jborysowski@interia.pl.
[Ti] Título:A3R Phage and Staphylococcus aureus Lysate Do Not Induce Neutrophil Degranulation.
[So] Source:Viruses;9(2), 2017 Feb 21.
[Is] ISSN:1999-4915
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:The objective of this study was to evaluate the effects of A3R phage and lysate obtained after phage infection on neutrophil degranulation. The exocytosis of primary and secondary granules from neutrophils was investigated in vitro in whole blood specimens by flow cytometry based on the expression of specific markers of exocytosis (CD63 for primary granules and CD66b for secondary granules). We found that both A3R and lysate had no significant effect on the exocytosis of primary and secondary granules. These data suggest that neither A3R virions nor any products of phage-induced lysis of are likely to induce neutrophil degranulation in patients who are treated with phage preparations. Since neutrophil granules contain some potentially toxic proteins, our results provide an important argument for the safety of phage therapy. Moreover, these data indicate that the induction of neutrophil degranulation is not likely to contribute to antibacterial effects of phages.
[Mh] Termos MeSH primário: Bacteriólise
Degranulação Celular
Neutrófilos/imunologia
Fagos de Staphylococcus/imunologia
Staphylococcus aureus/imunologia
[Mh] Termos MeSH secundário: Adulto
Exocitose
Citometria de Fluxo
Voluntários Saudáveis
Seres Humanos
Terapia por Fagos/efeitos adversos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170926
[Lr] Data última revisão:
170926
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170224
[St] Status:MEDLINE


  10 / 52 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28007922
[Au] Autor:Oechslin F; Piccardi P; Mancini S; Gabard J; Moreillon P; Entenza JM; Resch G; Que YA
[Ad] Endereço:Department of Fundamental Microbiology, University of Lausanne, Switzerland
[Ti] Título:Synergistic Interaction Between Phage Therapy and Antibiotics Clears Pseudomonas Aeruginosa Infection in Endocarditis and Reduces Virulence.
[So] Source:J Infect Dis;215(5):703-712, 2017 03 01.
[Is] ISSN:1537-6613
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Background: Increasing antibiotic resistance warrants therapeutic alternatives. Here we investigated the efficacy of bacteriophage-therapy (phage) alone or combined with antibiotics against experimental endocarditis (EE) due to Pseudomonas aeruginosa, an archetype of difficult-to-treat infection. Methods: In vitro fibrin clots and rats with aortic EE were treated with an antipseudomonas phage cocktail alone or combined with ciprofloxacin. Phage pharmacology, therapeutic efficacy, and resistance were determined. Results: In vitro, single-dose phage therapy killed 7 log colony-forming units (CFUs)/g of fibrin clots in 6 hours. Phage-resistant mutants regrew after 24 hours but were prevented by combination with ciprofloxacin (2.5 × minimum inhibitory concentration). In vivo, single-dose phage therapy killed 2.5 log CFUs/g of vegetations in 6 hours (P < .001 vs untreated controls) and was comparable with ciprofloxacin monotherapy. Moreover, phage/ciprofloxacin combinations were highly synergistic, killing >6 log CFUs/g of vegetations in 6 hours and successfully treating 64% (n = 7/11) of rats. Phage-resistant mutants emerged in vitro but not in vivo, most likely because resistant mutations affected bacterial surface determinants important for infectivity (eg, the pilT and galU genes involved in pilus motility and LPS formation). Conclusions: Single-dose phage therapy was active against P. aeruginosa EE and highly synergistic with ciprofloxacin. Phage-resistant mutants had impaired infectivity. Phage-therapy alone or combined with antibiotics merits further clinical consideration.
[Mh] Termos MeSH primário: Antibacterianos/farmacologia
Endocardite/terapia
Terapia por Fagos/métodos
Infecções por Pseudomonas/terapia
Pseudomonas aeruginosa/efeitos dos fármacos
[Mh] Termos MeSH secundário: Animais
Ciprofloxacino/farmacologia
Farmacorresistência Bacteriana Múltipla
Endocardite/microbiologia
Feminino
Testes de Sensibilidade Microbiana
Pseudomonas aeruginosa/patogenicidade
Ratos
Ratos Wistar
Virulência
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 5E8K9I0O4U (Ciprofloxacin)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170715
[Lr] Data última revisão:
170715
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:161224
[St] Status:MEDLINE
[do] DOI:10.1093/infdis/jiw632



página 1 de 6 ir para página                
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde